With eyes on expanding in North America and around the globe, Biocon has been busy in recent months.
Biocon Generics, a unit of India’s Biocon Limited, just acquired (PDF) Eywa Pharma’s New Jersey solid dosage manufacturing plant for $7.7 million.
With the Eywa deal, Biocon gets a plant with potential capacity to grow production to up to 2 billion tablets or capsules per year, Biocon said. The purchase expands the company’s foothold in the U.S. as well. Eywa employees at the plant will join Biocon's workforce.
Separately, the company’s Biocon Biologics unit completed the integration of Viatris’ biosimilars franchise in North America. With this development, Biocon is now leading commercial operations in the U.S. and Canada for the group, which it recently bought for $3.3 billion.
Biocon Biologics expects to expand its number of employees in North America by 150 by the end of the year.
With the Viatris deal, Biocon received full control of Semglee, a biosimilar referencing Sanofi’s blockbuster insulin med Lantus and the first FDA-approved interchangeable biosimilar.
Biocon has previously said that the complete Viatris biosimilar portfolio will generate an estimated $875 million revenues in 2022, and the number could surpass $1 billion in 2023.
The North American integration followed similar efforts in emerging markets, Biocon Biologics CEO Shreehas Tambe said in a statement.